European Patients' Academy on Therapeutic Innovation (EUPATI)

In association with

Association for the Protection of Patients' Rights – SR, The Slovak Medical University in Bratislava and ISPOR Slovakia OZ

Invite you to join us at the press conference:

THE PATIENT AND INNOVATIONS IN MEDICINE

When the European Patients' Academy on Therapeutic Innovation was established three years ago, its goal was to initiate discussion, most of all on the status of patients in the fields of innovative medicine as a necessary prerequisite to availability of modern and effective treatment. After three years of work in the European environment, it has become apparent that from the perspective of innovation, there is a lack of clarity in the relationship between patients and healthcare. This lack of clarity needs to be discussed and resolved.

With this press conference, the European Patients' Academy on Therapeutic Innovation would like to introduce its project and announce preparations for the 1st national EUPATI conference. The conference will also be supported by Ms. Nicola Bedlington, Secretary General at the European Patients' Forum in Brussels and project coordinator of the EUPATI project.

At the conference, information about the project will be available from:

- Nicola Bedlington, Secretary General at the European Patients' Forum in Brussels and project coordinator of the EUPATI project
- Dominik Tomek, for the National contact team EUPATI Slovakia
- Katarína Kafková, for the Association for the Protection of Patients' Rights SR
- Jozef Holomáň, for the Patients' education Academy at the Slovak Medical University Faculty of Medicine
- Marica Laščeková, listener at the EUPATI Academy

We'll meet:

On the 3rd of December 2015 at 14:00 in the meeting room of the European information center, Palisády 5029/29, 811 06 Bratislava

We'd be delighted if you'd accept our invitation.

Please call: 0903 605 329 or e-mail: gudiakova@snowball.sk if you intend to participate.

The EUPATI project is supported Joint Initiative for Innovative Medicines (http://www.imi.europa.eu/) based on grant agreement no. 115334, financed from contributions by the Seventh Framework Programme of the European Union (FP7/2007-2013 – IMI 1) and IMI 2 for 2014 – 2014 and the pharmaceutical industry association EFPIA.

